Xencor, Inc. (NASDAQ:XNCR) CEO Bassil I. Dahiyat Sells 3,366 Shares

Xencor, Inc. (NASDAQ:XNCRGet Free Report) CEO Bassil I. Dahiyat sold 3,366 shares of the business’s stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $24.02, for a total value of $80,851.32. Following the sale, the chief executive officer now directly owns 352,615 shares of the company’s stock, valued at $8,469,812.30. This represents a 0.95 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Xencor Price Performance

Shares of NASDAQ XNCR traded down $0.70 during trading hours on Friday, hitting $22.80. 264,087 shares of the stock were exchanged, compared to its average volume of 599,219. The company’s fifty day simple moving average is $20.84 and its two-hundred day simple moving average is $20.37. The company has a market cap of $1.60 billion, a PE ratio of -7.34 and a beta of 0.66. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.23 and a current ratio of 6.23. Xencor, Inc. has a 1-year low of $15.31 and a 1-year high of $26.84.

Xencor (NASDAQ:XNCRGet Free Report) last released its earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.98) by $0.27. The business had revenue of $10.70 million during the quarter, compared to the consensus estimate of $14.59 million. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. The company’s revenue for the quarter was down 81.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.40) EPS. On average, sell-side analysts predict that Xencor, Inc. will post -3.79 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the stock. Royal Bank of Canada raised their price target on shares of Xencor from $31.00 to $34.00 and gave the stock an “outperform” rating in a research note on Thursday, September 26th. JPMorgan Chase & Co. boosted their price target on shares of Xencor from $27.00 to $28.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $34.00 target price (up previously from $32.00) on shares of Xencor in a research report on Friday, November 8th. Finally, Wedbush reissued an “outperform” rating and set a $38.00 price target on shares of Xencor in a research report on Thursday, November 7th. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Xencor presently has a consensus rating of “Moderate Buy” and an average target price of $35.75.

Read Our Latest Analysis on XNCR

Institutional Investors Weigh In On Xencor

Several large investors have recently modified their holdings of the company. Baker BROS. Advisors LP boosted its position in shares of Xencor by 22.9% during the 3rd quarter. Baker BROS. Advisors LP now owns 670,431 shares of the biopharmaceutical company’s stock valued at $13,482,000 after purchasing an additional 125,000 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. grew its stake in shares of Xencor by 8.5% in the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 12,156 shares of the biopharmaceutical company’s stock valued at $244,000 after buying an additional 949 shares during the period. Erste Asset Management GmbH bought a new stake in Xencor in the 3rd quarter valued at about $7,087,000. Braidwell LP acquired a new position in Xencor during the 3rd quarter worth approximately $9,380,000. Finally, Rockefeller Capital Management L.P. bought a new position in Xencor in the third quarter worth approximately $205,000.

About Xencor

(Get Free Report)

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.

Recommended Stories

Insider Buying and Selling by Quarter for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.